The First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, 730000, China.
J Orthop Surg Res. 2024 Mar 30;19(1):205. doi: 10.1186/s13018-024-04701-3.
Ferroptosis is known to play a crucial role in diabetic osteopathy. However, key genes and molecular mechanisms remain largely unclear. This study aimed to identify a crucial ferroptosis-related differentially expressed gene (FR-DEG) in diabetic osteopathy and investigate its potential mechanism.
We identified fibronectin type III domain-containing protein 5 (FNDC5)/irisin as an essential FR-DEG in diabetic osteopathy using the Ferroptosis Database (FerrDb) and GSE189112 dataset. Initially, a diabetic mouse model was induced by intraperitoneal injection of streptozotocin (STZ), followed by intraperitoneal injection of irisin. MC3T3-E1 cells treated with high glucose (HG) were used as an in vitro model. FNDC5 overexpression plasmid was used to explore underlying mechanisms in vitro experiments. Femurs were collected for micro-CT scan, histomorphometry, and immunohistochemical analysis. Peripheral serum was collected for ELISA analysis. Cell viability was assessed using a CCK-8 kit. The levels of glutathione (GSH), malondialdehyde (MDA), iron, reactive oxygen species (ROS), and lipid ROS were detected by the corresponding kits. Mitochondria ultrastructure was observed through transmission electron microscopy (TEM). Finally, mRNA and protein expressions were examined by quantitative real-time PCR (qRT-PCR) and western blot analysis.
The expression of FNDC5 was found to be significantly decreased in both in vivo and in vitro models. Treatment with irisin significantly suppressed ferroptosis and improved bone loss. This was demonstrated by reduced lipid peroxidation and iron overload, increased antioxidant capability, as well as the inhibition of the ferroptosis pathway in bone tissues. Furthermore, in vitro studies demonstrated that FNDC5 overexpression significantly improved HG-induced ferroptosis and promoted osteogenesis. Mechanistic investigations revealed that FNDC5 overexpression mitigated ferroptosis in osteoblasts by inhibiting the eukaryotic initiation factor 2 alpha (eIF2α)/activated transcription factor 4 (ATF4)/C/EBP-homologous protein (CHOP) pathway.
Collectively, our study uncovered the important role of FNDC5/irisin in regulating ferroptosis of diabetic osteopathy, which might be a potential therapeutic target.
铁死亡在糖尿病性骨病中起着至关重要的作用。然而,关键基因和分子机制在很大程度上仍不清楚。本研究旨在鉴定糖尿病性骨病中的关键铁死亡相关差异表达基因(FR-DEG),并探讨其潜在机制。
我们使用铁死亡数据库(FerrDb)和 GSE189112 数据集鉴定纤维连接蛋白 III 型结构域包含蛋白 5(FNDC5)/鸢尾素为糖尿病性骨病中的关键 FR-DEG。首先,通过腹腔注射链脲佐菌素(STZ)诱导糖尿病小鼠模型,随后腹腔注射鸢尾素。用高糖(HG)处理 MC3T3-E1 细胞作为体外模型。使用 FNDC5 过表达质粒进行体外实验的机制研究。收集股骨进行 micro-CT 扫描、组织形态计量学和免疫组织化学分析。收集外周血清进行 ELISA 分析。用 CCK-8 试剂盒评估细胞活力。用相应试剂盒检测谷胱甘肽(GSH)、丙二醛(MDA)、铁、活性氧(ROS)和脂质 ROS 的水平。用透射电子显微镜(TEM)观察线粒体超微结构。最后,通过定量实时 PCR(qRT-PCR)和 Western blot 分析检测 mRNA 和蛋白表达。
体内和体外模型均显示 FNDC5 的表达明显降低。用鸢尾素处理可显著抑制铁死亡并改善骨丢失。这表现为脂质过氧化和铁过载减少、抗氧化能力增强以及骨组织中铁死亡途径的抑制。此外,体外研究表明 FNDC5 过表达可显著改善 HG 诱导的铁死亡并促进成骨。机制研究表明 FNDC5 过表达通过抑制真核起始因子 2 ɑ(eIF2ɑ)/激活转录因子 4(ATF4)/C/EBP 同源蛋白(CHOP)通路抑制破骨细胞中铁死亡。
总之,本研究揭示了 FNDC5/鸢尾素在调节糖尿病性骨病中铁死亡中的重要作用,这可能是一个潜在的治疗靶点。